Prevalence of Fabry disease in male patients with unexplained left ventricular hypertrophy in primary cardiology practice: Prospective Fabry cardiomyopathy screening study (FACSS)

Journal of Inherited Metabolic Disease

Volumn 37, Issue 3, 2014, Pages 455-460

  Palecek, Tomas ^a,b   Honzikova, Jitka ^c   Poupetova, Helena ^c   Vlaskova, Hana ^c   Kuchynka, Petr ^a,b   Golan, Lubor ^a   Magage, Sudheera ^a   Linhart, Ales ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

^b ST ANNE S UNIVERSITY HOSPITAL   (Czech Republic)

^c Charles University in Prague and General University Hospital in Prague   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA GALACTOSIDASE;

ADULT; AGED; ANHIDROSIS; ARTICLE; CARDIOLOGIST; CARDIOLOGY; CARDIOVASCULAR PARAMETERS; CARDIOVASCULAR SYSTEM EXAMINATION; CLINICAL PRACTICE; DRIED BLOOD SPOT TESTING; ECHOCARDIOGRAPHY; ENZYME ACTIVITY; ENZYME ANALYSIS; FABRY DISEASE; GENE MUTATION; GENETIC ANALYSIS; GENETIC SCREENING; HEARING IMPAIRMENT; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FUNCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE OUTFLOW TRACT OBSTRUCTION; HEART LEFT VENTRICLE SYSTOLIC FUNCTION; HUMAN; INTRON; LEUKOCYTE; MAJOR CLINICAL STUDY; MALE; MAXIMAL WALL THICKNESS; MICROALBUMINURIA; PROSPECTIVE STUDY; CARDIOMYOPATHIES; COMPLICATION; HYPERTROPHY, LEFT VENTRICULAR; METABOLISM; MIDDLE AGED; PREVALENCE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ALPHA-GALACTOSIDASE; CARDIOMYOPATHIES; FABRY DISEASE; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; MALE; MIDDLE AGED; PREVALENCE; PROSPECTIVE STUDIES; VENTRICULAR FUNCTION, LEFT;

EID: 84904202675     PISSN: 01418955     EISSN: 15732665     Source Type: Journal    
DOI: 10.1007/s10545-013-9659-2     Document Type: Article

References (35)

1. Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, Bork P, Kondrashov AS, Sunyaev SR (2010) A method and server for predicting damaging missense mutations. Nat Methods 7(4):248-249
2. Arad M, Maron BJ, Gorham JM et al (2005) Glycogen storage diseases presenting as hypertrophic cardiomyopathy.N Engl JMed 352:362-372
3. Banikazemi M, Bultas J, Waldek S et al (2007) Agalsidase-beta therapy for advanced Fabry disease: a randomized trial. Ann Intern Med 146:77-86 (Pubitemid 351640010)
4. Brady RO, Gal AE, Bradley RMet al (1967) Enzymatic defect in Fabry's disease. Ceramidetrihexoside deficiency. N Engl J Med 276:1163-1967
5. Chamoles NA, Blanco M, Gaggioli D (2001) Fabry disease: enzymatic diagnosis in dried blood spots on filter paper. Clin Chim Acta 308:195-196 (Pubitemid 32537628)
6. Chimenti C, Pieroni M, Morgante E et al (2004) Prevalence of Fabry disease in female patients with late-onset hypertrophic cardiomyopathy. Circulation 110:1047-1053 (Pubitemid 39319001)
7. Davies JP, Winchester BG, Malcolm S (1993) Mutation analysis in patients with the typical form of Anderson-Fabry disease. Hum Mol Genet 2:1051-1053 (Pubitemid 23216645)
8. Elleder M, Dorazilová V, Bradová V et al (1990) Fabry's disease with isolated disease of the cardiac muscle, manifesting as hypertrophic cardiomyopathy. Cas Lek Cesk 129:369-372
9. Elliott P, Andersson B, Arbustini E et al (2008) Classification of the cardiomyopathies: a position statement from the European Society Of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J 29:270-276
10. Elliott P, Baker R, Pasquale F et al (2011) Prevalence of Anderson-Fabry disease in patients with hypertrophic cardiomyopathy: the European Anderson-Fabry Disease survey. Heart 97:1957-1960
11. Eng CM, Germain DP, Banikazemi M (2006) Fabry disease: guidelines for the evaluation and management of multi-organ system involvement. Genet Med 8:539-548 (Pubitemid 44402030)
12. GenBank - genomic DNA NG-007119.1 (www.ncbi.nlm.nih.gov/nuccore/NG- 007119.1), mRNA NM-000169.2 (www.ncbi.nlm.nih.gov/nuccore/NM-000169.2 (PRI 02-SEP-2013)
13. Hagège AA, Caudron E, Damy T et al (2011) Screening patients with hypertrophic cardiomyopathy for Fabry disease using a filter-paper test: the FOCUS study. Heart 97:131-136
14. Imbriaco M, Pisani A, Spinelli L et al (2009) Effects of enzyme-replacement therapy in patients with Anderson-Fabry disease: a prospective long-term cardiac magnetic resonance imaging study. Heart 95:1103-1107
15. Kampmann C, Linhart A, Baehner F et al (2008) Onset and progression of the Anderson-Fabry disease related cardiomyopathy. Int J Cardiol 130:367-373
16. Konno T, Chang S, Seidman JG et al (2010) Genetics of hypertrophic cardiomyopathy. Curr Opin Cardiol 25:205-209
17. Kotanko P, Kramar R, Devrnja D et al (2004) Results of a nationwide screening forAnderson-Fabry disease among dialysis patients. JAm Soc Nephrol 15:1323-1329 (Pubitemid 38526014)
18. Linhart A, Elliott PM (2007) The heart in Anderson-Fabry disease and other lysosomal storage disorders. Heart 93:528-535 (Pubitemid 46631530)
19. Linhart A, Palecek T, Bultas J et al (2000) New insights in cardiac structural changes in patients with Fabry's disease. Am Heart J 139:1101-1108 (Pubitemid 30390343)
20. Linhart A, Lubanda JC, Palecek T et al (2001) Cardiac manifestations in Fabry disease. J Inherit Metab Dis 24(Suppl 2):75-83 (Pubitemid 33061636)
21. Linhart A, Kampmann C, Zamorano JL et al (2007) Cardiac manifestations of Anderson-Fabry disease: results from the international Fabry outcome survey. Eur Heart J 28:1228-1235 (Pubitemid 47343855)
22. Lukacs Z, Hartung R, Beck M et al (2007) Direct comparison of enzyme measurements from dried blood and leukocytes from male and female Fabry disease patients. J Inherit Metab Dis 30:614
23. Maron BJ, Gardin JM, Flack JM et al (1995) Prevalence of hypertrophic cardiomyopathy in a general population of young adults: echocardiographic analysis of 4111 subjects in the CARDIA study. Circulation 92:785-789
24. Mayes JS, Scheerer JB, Sifers RN et al (1981) Differential assay for lysosomal alpha-galactosidases in human tissues and its application to Fabry's disease. Clin Chim Acta 112:247-251 (Pubitemid 11156261)
25. Mehta A, Clarke JT, Giugliani R et al (2009) Natural course of Fabry disease: changing pattern of causes of death in FOS - Fabry Outcome Survey. J Med Genet 46:548-552
26. Merta M, Reiterova J, Ledvinova J et al (2007) A nationwide blood spot screening study for Fabry disease in the Czech Republic haemodialysis patient population. Nephrol Dial Transplant 22:179-186 (Pubitemid 46050343)
27. Monserrat L, Gimeno-Blanes JR,Marín F et al (2007) Prevalence of fabry disease in a cohort of 508 unrelated patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 50:2399-2403 (Pubitemid 50011583)
28. Moon JC, Sheppard M, Reed E et al (2006) The histological basis of late gadolinium enhancement cardiovascular magnetic resonance in a patient with Anderson-Fabry disease. J Cardiovasc Magn Reson 8: 479-482
29. Nakao S, Takenaka T, Maeda M et al (1995) An atypical variant of Fabry's disease in men with left ventricular hypertrophy. N Engl J Med 333:288-293
30. Ommen SR, Nishimura RA, EdwardsWD (2003) Fabry disease: amimic for obstructive hypertrophic cardiomyopathy? Heart 89:929-930 (Pubitemid 36920824)
31. Palecek T, Linhart A, Magage S et al (2005) Multicentrický screening Fabryho choroby u jedinců s nevysvětlitelnou hypertrofií levé komory. (Fabry Cardiomyopathy Screening Study-FACSS): desing of the study. Cor Vasa 47:242-245
32. Richard P, Charron P, Carrier L et al (2003) Hypertrophic cardiomyopathy: distribution of disease genes, spectrum of mutations, and implications for a molecular diagnosis strategy. Circulation 107:2227-2232 (Pubitemid 36547217)
33. Sachdev B, Takenaka T, Teraguchi H et al (2002) Prevalence of Anderson-Fabry disease in male patients with late onset hypertrophic cardiomyopathy. Circulation 105:1407-1411 (Pubitemid 34263268)
34. Schwarz JM, Rödelsperger C, Schuelke M, Seelow D (2010) MutationTaster evaluates disease-causing potential of sequence alterations. Nat Methods. 7(8):575-6.
35. Spada M, Pagliardini S (2002) Screening for Fabry disease in end-stage nephropathies. J Inherit Metab Dis 25(Suppl 1):113